Concepedia

Matthew Wintle

MW

Statistics

Publications

10

Citations

1.6K

H-Index

10

Active since

2004

Affiliations

Eli Lilly (United States)(Current)

Amplyx Pharmaceuticals (United States)

University of North Carolina at Chapel Hill

University of California, Davis

Mills Peninsula Health Services

Matthew Wintle is an author at Eli Lilly (United States) specializing in diabetes mellitus, diabetology, and diabetes pharmacotherapy.

Publications per year

2004–2009

10

Publications

10

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

David C. Klonoff, John B. Buse, Loretta L. Nielsen et al. · Current Medical Research and Opinion · 2007 · 700 citations

, , +13

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

John B. Buse, David C. Klonoff, Loretta L. Nielsen et al. · Clinical Therapeutics · 2007 · 280 citations

, , +17

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

David C. Klonoff, John B. Buse, Loretta L. Nielsen et al. · Current Medical Research and Opinion · 2008 · 227 citations

, , +13

A randomized, open-label, crossover study examiningthe effect of injection site on bioavailability of exenatide (synthetic exendin-4)

Federico Calara, Kristin Taylor, Jenny Han et al. · Clinical Therapeutics · 2005 · 94 citations

, , +6

Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin‐4) in Healthy Subjects

E. Blase, Kristin Taylor, Hong‐ye Gao et al. · The Journal of Clinical Pharmacology · 2005 · 82 citations

, , +12

1–5 of 10